C4 Therapeutics (CCCC) Stock: Buy, Sell, or Hold?
CCCC - C4 Therapeutics, Inc.
$3.51
0.11 (3.24%)
▲
5d:
-6.15%
30d:
-10.0%
90d:
-9.3%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CCCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CCCC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CCCC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CCCC is currently trading at $3.51, which is considered oversold relative to its 30-day fair value range of $3.59 to $4.12.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $3.31, while resistance sits at $4.10. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: CCCC scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.33 (+279.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $3.31, while resistance sits at $4.10. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: CCCC scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.33 (+279.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.59 -
$4.12
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 279.9% below Wall St target ($13.33)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.59 -
$4.12
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.31
Resistance Level
$4.10
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.52
Wall Street Target
$13.33
(+279.9%)
Revenue Growth (YoY)
2.8%
Profit Margin
-289.4%
Share & Embed Analysis
Last updated: September 11, 2026 9:19 PM ET
Data refreshes hourly during market hours. Next update: 10:19 PM
Data refreshes hourly during market hours. Next update: 10:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CCCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
